A practical reference on HGF mimetic: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-16 and is reviewed periodically as new material appears.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
In 1948, the Australian psychiatrist John Cade discovered the usefulness of lithium salts in treating mania while working at the Bundoora Repatriation Mental Hospital in Melbourne. He was injecting guinea pigs with urine extracts taken from manic patients in an attempt to isolate a metabolic compound which might be causing mental symptoms. Since uric acid in gout was known to be psychoactive, he needed soluble urate for a control. He used lithium urate, already known to be the most soluble urate compound, and observed that it caused the guinea pigs to become tranquil. Cade traced the effect to the lithium ion itself, and after Cade ingested lithium himself to ensure its safety in humans, he proposed lithium salts as tranquilizers. In 1949, he published his findings in the Medical Journal of Australia in a paper entitled "Lithium salts in the treatment of psychotic excitement". He soon succeeded in controlling mania in chronically hospitalized patients with lithium. This was one of the first successful applications of a drug to treat mental illness, and it opened the door for the development of medicines for other mental problems in the next decades. In 1950, one of Cade's first patients died of lithium toxicity after Cade had successfully treated him and released him from the hospital. Afterward, Cade abandoned the research of lithium and focused instead on testing other salts of rubidium, cerium, and strontium for their potential utility in psychiatry.
In polymer chemistry, the molar mass distribution (or molecular weight distribution) describes the relationship between the number of moles of each polymer species (Ni) and the molar mass (Mi) of that species. In linear polymers, the individual polymer chains rarely have exactly the same degree of polymerization and molar mass, and there is always a distribution around an average value. The molar mass distribution of a polymer may be modified by polymer fractionation.
== Spin-offs and sequel == WayneRadioTV has produced several spin-offs, including Half-Life: Alyx but the Gnome Is Too Aware, which started in 2021 and ended in 2023 after a year long hiatus. It follows the same player carrying a conscious garden gnome voiced using text-to-speech from hidden actors, to the end of the game. A sequel to the original series, titled Half-Life 2 VR but the AI is Self-Aware, began in March 2026, and is ongoing as of August 2026.
Whereas the biological half-life of estradiol given by intravenous injection is about 0.5 to 2 hours, the biological half-life of oral estradiol has a range of 13 to 20 hours due to the large and long-lasting pool of estrogen conjugates that is formed during first-pass metabolism and that serves to continuously replenish circulating estradiol levels.
In April 2012, the government announced additional spending cuts in education and healthcare of 10 billion euros, which raised protests from the affected sectors. On May 22, 2012, the first general education strike in the history of Spain took place. Only three days later, on May 25, it was known that Bankia, nationalized two weeks earlier, would need an injection of 19 billion euros of public money to be cleaned up, highlighting the fragility of the Spanish banking system. On June 9, Finance Minister Luis de Guindos announced that Spain was going to ask for a financial rescue from the European Union for a maximum value of 100 billion euros to clean up the savings banks with problems, although he refused to use the term "rescue" and preferred the term "credit on very favorable terms". The same was done by President Mariano Rajoy in his speech the following day who used the term "credit line". However, the harsh policies of adjustment and "structural reforms" implemented by the government did not manage to stop the escalation of the risk premium which in July 2012 exceeded 600 basis points with respect to the German bond, a level that made it practically impossible to finance Spanish debt in the markets, so it seemed inevitable that the government would ask for the "rescate" as Greece, Ireland and Portugal had already done. On July 11, President Rajoy said in the Congress of Deputies:
Sources: en.wikipedia.org
=== Cholesterol === In 1997, the FDA recognized the cholesterol lowering effect of oat β-glucan. In Europe, several health claim requests were submitted to the EFSA NDA Panel (Dietetic Products, Nutrition and Allergies), related to the role of β-glucans in maintenance of normal blood cholesterol concentrations and maintenance or achievement of a normal body weight. In July 2009, the Scientific Committee issued the following statements:
== Mechanisms == The mechanism by which dedifferentiation occurs has not been completely illuminated. The pathways discussed below are found to be closely related to dedifferentiation and regeneration in some species. Because not one pathway has been elucidated as necessary for all dedifferentiation and regeneration, the mechanism may function differently in different species.
In a move seen as marking her return to political life, former prime minister Liz Truss writes an article for The Sunday Telegraph in which she says her economic agenda was never given a "realistic chance". 6 February 2022–2023 National Health Service strikes: Ambulance staff and nurses walk out, with further disruption to follow in the week, in what is expected to be the biggest-ever round of NHS strikes. Foreign Secretary James Cleverly offers his condolences to victims of the 7.8 magnitude Turkey–Syria earthquake and says the UK is deploying emergency response teams, including 76 search and rescue specialists, equipment and rescue dogs. The government issues an urgent warning to British travellers and holidaymakers who may be in or planning to visit the region. 7 February Former Met Police officer David Carrick, one of the UK's most prolific sex offenders, is sentenced at Southwark Crown Court to 36 life sentences with a minimum term of 30 years in prison. Sunak performs a cabinet reshuffle. Greg Hands is named as the new Conservative Party chairman; Grant Shapps becomes the secretary of state for energy, security and net zero in a newly-formed department; Kemi Badenoch is appointed as the first secretary of state at the newly created Department for Business and Trade, with continued responsibility as equalities minister. 8 February Ukraine's President Volodymyr Zelensky addresses a joint session of Parliament during his first visit to the UK since Russia invaded his country. He later visits Buckingham Palace for a meeting with the King.
ATPases (EC 3.6.1.3, Adenosine 5'-TriPhosphatase, adenylpyrophosphatase, ATP monophosphatase, triphosphatase, ATP hydrolase, adenosine triphosphatase) are a class of enzymes that catalyze the decomposition of ATP into ADP and a free phosphate ion or the inverse reaction. This dephosphorylation reaction releases energy, which the enzyme (in most cases) harnesses to drive other chemical reactions that would not otherwise occur. This process is widely used in all known forms of life. Some such enzymes are integral membrane proteins (anchored within biological membranes), and move solutes across the membrane, typically against their concentration gradient. These are called transmembrane ATPases.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.